Optimal Scheduling of Bevacizumab and Pemetrexed/cisplatin Dosing in Non‐Small Cell Lung Cancer - Inria - Institut national de recherche en sciences et technologies du numérique Accéder directement au contenu
Article Dans Une Revue CPT: Pharmacometrics and Systems Pharmacology Année : 2019

Optimal Scheduling of Bevacizumab and Pemetrexed/cisplatin Dosing in Non‐Small Cell Lung Cancer

Résumé

Bevacizumab-pemetrexed/cisplatin (BEV-PEM/CIS) is a first line therapeutic for advanced non-squamous non-small cell lung cancer (NSCLC). Bevacizumab potentiates PEM/CIS cytotoxicity by inducing transient tumor vasculature normalization. BE V- PEM/CIS has a narrow therapeutic window. Therefore, it is an attractive target for administration schedule optimization. The present study leverages our previous work on BEV-PEM/CIS pharmacodynamic modeling in NSCLC-bearing mice to estimate the optimal gap in the scheduling of sequential BEV-PEM/CIS. We predicted the optimal gap in BEV-PEM/CIS dosing to be 2.0 days in mice and 1.2 days in humans. Our simulationssuggest that the efficacy loss in scheduling BEV-PEM/CIS at too great of a gap is much less than the efficacy loss in scheduling BEV-PEM/CIS at too short of a gap.
Fichier principal
Vignette du fichier
19_schneider.pdf (1.19 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-02109335 , version 1 (24-04-2019)

Identifiants

Citer

Benjamin K Schneider, Arnaud Boyer, Joseph Ciccolini, Fabrice Barlesi, Kenneth Wang, et al.. Optimal Scheduling of Bevacizumab and Pemetrexed/cisplatin Dosing in Non‐Small Cell Lung Cancer. CPT: Pharmacometrics and Systems Pharmacology, 2019, ⟨10.1002/psp4.12415⟩. ⟨hal-02109335⟩
144 Consultations
175 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More